^
Association details:
| Biomarker: | ZNF765 overexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | navitoclax (ABT 263) (Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ZNF765 is a prognostic biomarker of hepatocellular carcinoma associated with cell cycle, immune infiltration, m6A modification, and drug susceptibility
Published date:
07/04/2023
Excerpt:
Tumors being resistant to the drug may be the chief cause of the poor effects of chemotherapy in hepatocellular carcinoma....Additionally, the result of the drug susceptibility analysis illustrated that cells with high ZNF765 expression were sensitive to 20 drugs, while they were resistant to Docetaxel, 17-AAG, and Bleomycin (Figure 10G).
DOI:
10.18632/aging.204827
